ORIGINAL RESEARCH article
Front. Med.
Sec. Hematology
Immuno-protective Impact of Kangfuxin liquid on Systematic Toxicity Associated with Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
Provisionally accepted
- The Affiliated Hospital of Guilin Medical University, Guilin, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: This study evaluated the effectiveness of Kangfuxin liquid against autologous stem cell transplantation toxicity in patients with multiple myeloma. Methods: This single-center retrospective study involved 82 participants, divided into the simple oral cryotherapy group (control group), which included 43 patients with multiple myeloma who underwent autologous hematopoietic stem cell transplantation before May 2023, and the Kangfuxin liquid + oral cryotherapy group (experimental group, which included 39 patients with multiple myeloma, who underwent autologous hematopoietic stem cell transplantation after June 2023. Statistical analysis indicators included infection, gastrointestinal toxic side effects, efficacy evaluation, and prognostic analysis. Results: Compared with the control group, the experimental group had a higher mean age (p = 0.003), fewer reinfused stem cells (p < 0.001), and a longer neutrophil and platelet engraftment time (p = 0.001 and p < 0.001). The experimental group had lower auxiliary treatment costs (p < 0.0001), and significantly lower infection incidence (p = 0.001) and mucositis and diarrhea grading (p = 0.046), indicating a protective effect. There were no additional adverse reactions, and the treatment efficacy for the patients' primary diseases remained unaffected. Conclusion: Kangfuxin liquid significantly reduces mucosal damage, shortens hospitalization, lowers medical costs, and does not compromise the therapeutic efficacy of autologous transplantation for multiple myeloma, providing evidence for clinical treatment.
Keywords: Autologous hematopoietic stem cell transplantation, High-dose melphalan, Kangfuxin Liquid, Multiple Myeloma, Toxicity
Received: 07 Sep 2025; Accepted: 20 Nov 2025.
Copyright: © 2025 Wu, Tang, Deng, Qu, Jiang, Zhou, Lin and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xiaotao Wang, wxttjl@126.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.